120209-22-5

Usage

Uses

Used in Pharmaceutical Industry:
Quinoline, 6-hydrazino-, Monohydrochloride is used as a key intermediate in the synthesis of various pharmaceuticals for the development of new drugs. Its unique chemical structure allows it to be incorporated into the design of potential therapeutic agents, targeting a range of diseases.
Used in Dye Industry:
In the dye industry, Quinoline, 6-hydrazino-, Monohydrochloride is used as a building block for the creation of new dyes. Its chemical properties contribute to the development of dyes with specific color characteristics and improved performance in various applications.
Used in Agrochemical Industry:
Quinoline, 6-hydrazino-, Monohydrochloride is used as a component in the formulation of agrochemicals, such as pesticides and herbicides. Its inclusion in these products can enhance their effectiveness in controlling pests and weeds, thereby improving agricultural productivity.
Used in Chemical Research:
As a reagent, Quinoline, 6-hydrazino-, Monohydrochloride is used in chemical research to facilitate the synthesis and study of various organic compounds. Its presence can aid in the understanding of chemical reactions and the development of new synthetic pathways.
Used in Organic Reactions:
Quinoline, 6-hydrazino-, Monohydrochloride is used as a catalyst in organic reactions, enhancing the rate and efficiency of these processes. Its catalytic properties can be harnessed to improve the synthesis of complex organic molecules, contributing to advancements in the field of organic chemistry.
Used in Medical Applications:
Quinoline, 6-hydrazino-, Monohydrochloride has potential applications in the treatment of various diseases, including cancer and neurodegenerative disorders. Its presence in drug formulations can contribute to the development of novel therapeutic strategies, offering new hope for patients suffering from these conditions.

Upstream product

• 580-15-4 6-aminoquinoline 

Downstream Products

• 897373-62-5 5-tert-butyl-2-quinolin-6-yl-2H-pyrazol-3-ylamine 

Relevant academic research and scientific papers

Insights into the modular design of kinase inhibitors and application to Abl and Axl

Scaffold hopping is a common strategy for generating kinase inhibitors that bind to the DFG-out inactive conformation. Small structural differences in inhibitor scaffolds can have significant effects on potency and selectivity across the kinome, however, these effects are often not studied in detail. Herein, we outline a design strategy to generate an array of DFG-out conformation inhibitors with three different hinge-binders and two DFG-pocket groups. We studied inhibitor selectivity across a large segment of the kinome and elucidated binding preferences that can be used in scaffold hopping campaigns. Using these analyses, we identified two selective inhibitors that display low nanomolar potency against Axl or wild-type and clinically relevant mutants of Abl.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

ENZYME MODULATORS AND TREATMENTS

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein ab1 kinase protein, bcr-ab1 kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.